Prana Biotechnology was established to commercialise research into age-related neurodegenerative disorders.
Prana Biotechnology (NASDAQ: PRAN)(ASX: PBT) a leading global developer of first-in-class treatments for neurodegenerative disease announced today, an update on the IMAGINE Phase 2 trial for Alzheimer's Disease and is pleased to report that 29 patients of the 42 patients originally enrolled into the trial have now completed treatment.
See More at Yahoo Finance
To learn more about Alzheimer's and Dementia care visit the Alzheimer's Reading Room
No comments:
Post a Comment